<DOC>
	<DOC>NCT00601159</DOC>
	<brief_summary>Primary objective of this study is to evaluate the efficacy of gemcitabine and cisplatin as first line therapy in patients with triple-negative MBC. 80 patients will be treated into this study.</brief_summary>
	<brief_title>Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC</brief_title>
	<detailed_description>Triple-negative breast tumors could contribute to the poor prognosis comparing with luminal A breast cancer.Fewer study has revealed that Cisplatin-based therapy may be effective for this type breast cancer.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Give written informed consent prior to study, with understanding that the patient has the right to withdraw from the study at any time without prejudice Be female and ≥18 and ≤75 years of age Be ambulatory and have ECOG performance stastus of ≤1 Have histological confirmed breast cancer,and the speciman confirmed ER negative,PR negatiev, and HER2 negative by immunochemistry technich of Fudan cancer hospital. Locally advanced or metastastic breast cancer who didn't receive firstline chemotherapy. No matter whether the patient has received anthracyclin or taxane treatment as neoadjuvant or adjuvant treatment. Have at least one target lesion according to the RECIST criteria. Exclusion criteria: Preganant or lactating women Advaced patient has received one or more chemotherapies Chemotherapy within four weeks preceding treatment start ECOG ≥ 2 Radiotherapy to the axial skeleton within the 4 weeks preceding study treatment start or insufficient recovery from the effects of prior radiotherapy Participation in any investigational drug study within 4 weeks preceeding treatment start Evidence of CNS metastasis History of another malignacy within the last five years except cured basal cell carcinoma of skin and carcinoma insitu of uterine cervix or a contralateral breast cancer Abnormal laboratory values: hemoglobin &lt; 8. 0g/dl, neutrophil&lt; 1.5×109/L, platelet&lt; 100×109/L. serum creatine &gt; upper limit of normal (ULN) serum bilirubin &gt; ULN ALT and AST &gt;5×ULN AKP &gt;5×ULN Serious uncontrolled intercurrence infection Life expectancy of less than 3 months</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>triple-negative Breast Cancer</keyword>
	<keyword>cisplatin</keyword>
	<keyword>chemotherapy</keyword>
</DOC>